Tag: gemtuzumab ozogamicin
Bristol Myers Squibb Acquires Orum Therapeutics’ ORM-6151 Program
Bristol Myers Squibb (BMS) has acquired Orum Therapeutics’ ORM-6151 program, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes.[1]
Pfizer to Acquire Seagen for US $ 43 Billion
Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...
BVX001 is Well-tolerated in Preclinical Study – Demonstrating a Favorable Safety...
Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).
Anti-CLL-1 ADC May Offer Effective and Safe Treatment Options for Patients...
Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed.
Today, the standard of care for AML is treatment...
Gemtuzumab Ozogamicin Granted Positive Opinion for Treatment of Previously Untreated, De...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
FDA Approval for Gemtuzumab Ozogamicin: Reintroduction Based on Favorable Risk:Benefit Profile
The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...
Antibody-drug Conjugates: Technologies and Global Markets
Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new. Due to many technological advances, recognition of appropriate target antigens, success...
What to Expect at PEGS Boston 2017: A New Pathway of...
From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...
Novel Cancer Therapeutics Drive Therapy Market
An increased need for better cancer treatment continues to boost the global cancer biological therapy market. According to a report published by Global Market...
